Rheumatoid Arthritis

Infliximab Biosimilar Only Moderately Less Expensive Than Reference Drug Under Medicare Part D
Researchers evaluating the cost benefits of biosimilars for the treatment of patients with rheumatoid arthritis found that the yearly annual prescription cost of the biosimilar, infliximab-dyyb, was 18% less than that of the brand name biologic, infliximab. Read More ›

Efficacy and Safety of Switching from Adalimumab to Sarilumab

This analysis evaluated the sustainability of clinical responses and improvements in physical function achieved on MONARCH at week 24 with continued sarilumab monotherapy, and assessed disease activity, physical function, and safety in adult patients switching from adalimumab to sarilumab.

Read More ›

Sustained Response in TARGET Study of Sarilumab + csDMARDs versus Placebo in RA Patients with Inadequate Response to TNF Inhibitors

The phase 3 TARGET study demonstrated that sarilumab (150 or 200 mg subcutaneously every 2 weeks [q2w]) plus conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) achieved clinical responses in terms of rheumatoid arthritis (RA) signs and symptoms and physical function compared with placebo in adults with active, moderate-to-severe RA who were intolerant of, or showed inadequate response to, tumor necrosis factor (TNF) inhibitors.

Read More ›

A previous study reported that highly sensitive cardiac troponin I (cTnI; >1.5 pg/mL) was an independent predictor of occult coronary plaque burden and composition on coronary computed tomography angiography (CTA) in patients with established rheumatoid arthritis (RA).

Read More ›

In the phase 3 TARGET study, sarilumab (150 or 200 mg) plus conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) improved RA signs and symptoms and physical function compared with placebo in adults with active, moderate-to-severe RA who were intolerant of, or showed inadequate response to, tumor necrosis factor (TNF) inhibitors.

Read More ›

The current study reported on updated integrated safety data from 8 randomized trials that further described the safety profile for up to 5.5 years of baricitinib in adult patients with moderately to severely active RA.

Read More ›

This is an analysis of the double-blind, placebo-controlled period 1 of the randomized phase 3 study that evaluated upadacitinib in patients with inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs).

Read More ›

Sarilumab, a human monoclonal antibody against interleukin-6 receptors, is currently approved for patients with moderate-to-severe rheumatoid arthritis (RA), based on efficacy and safety data from several clinical trials.

Read More ›

This post hoc analysis examined efficacy and safety outcomes from patients who completed the ASCERTAIN trial and switched to subcutaneous sarilumab 200 mg q2w.

Read More ›

The phase 3 SIRROUND-D trial demonstrated that sirukumab, a human monoclonal antibody that selectively binds to the interleukin-6 cytokine with high affinity, resulted in significant reduction in rheumatoid arthritis (RA) signs and symptoms, and inhibited radiographic progression at week 52 compared with placebo in patients with active RA despite disease-modifying antirheumatic drug (DMARD) treatment.

Read More ›

Page 1 of 3

Subscribe to
Rheumatology Practice Management

Stay up to date with rheumatology news & updates by subscribing to receive the free RPM print publications or weekly e‑Newsletter.

I'd like to receive: